Stemness-Suppressive Effect of Bibenzyl from
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
02
2021
accepted:
15
07
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Cancer stem-like cells (CSCs) are key mediators driving tumor initiation, metastasis, therapeutic failure, and subsequent cancer relapse. Thus, targeting CSCs has recently emerged as a potential strategy to improve chemotherapy. In this study, the anticancer activity and stemness-regulating capacity of 4,5,4'-trihydroxy-3,3'-dimethoxybibenzyl (TDB), a bibenzyl extracted from
Identifiants
pubmed: 34349823
doi: 10.1155/2021/5516655
pmc: PMC8328707
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5516655Informations de copyright
Copyright © 2021 Pornchanok Taweecheep et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Front Pharmacol. 2016 Oct 25;7:395
pubmed: 27826244
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Clin Exp Pharmacol Physiol. 2020 Jul;47(7):1311-1319
pubmed: 32124474
Clin Transl Med. 2018 Jul 9;7(1):18
pubmed: 29984391
Cell Oncol (Dordr). 2017 Oct;40(5):497-510
pubmed: 28677037
Front Immunol. 2018 Jun 19;9:1412
pubmed: 29971070
Development. 2014 Jun;141(11):2173-81
pubmed: 24866112
Front Oncol. 2017 May 05;7:80
pubmed: 28529925
Surg Oncol. 2013 Sep;22(3):156-61
pubmed: 23702313
Exp Mol Med. 2014 Jun 20;46:e101
pubmed: 24946789
PLoS Biol. 2009 Jun 2;7(6):e1000121
pubmed: 19492080
Stem Cell Reports. 2019 Jul 9;13(1):1-9
pubmed: 31257133
Front Immunol. 2020 Aug 07;11:1280
pubmed: 32849491
J Thorac Oncol. 2018 Mar;13(3):426-435
pubmed: 29326090
J Nat Med. 2018 Jun;72(3):615-625
pubmed: 29488156
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Cancer Manag Res. 2019 Jan 21;11:943-953
pubmed: 30718965
Cancer Cell. 2020 Dec 14;38(6):872-890.e6
pubmed: 33217342
Cell. 2005 Sep 23;122(6):947-56
pubmed: 16153702
J Mol Med (Berl). 2009 Nov;87(11):1097-104
pubmed: 19727638
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Case Rep Oncol. 2016 Apr 13;9(1):212-5
pubmed: 27194980
J Biol Chem. 2009 Jan 16;284(3):1612-9
pubmed: 18996844
Cancer Cell Int. 2015 Jul 15;15:71
pubmed: 26180516
J Thorac Oncol. 2014 Sep;9(9):1294-304
pubmed: 25036876
Cancer Lett. 2016 May 1;374(2):292-303
pubmed: 26940070
Acta Pharm Sin B. 2021 Jan;11(1):55-70
pubmed: 33532180
Oncotarget. 2017 Feb 21;8(8):14221-14250
pubmed: 27999207
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
J Nat Med. 2015 Oct;69(4):565-74
pubmed: 26109451
Protein Cell. 2018 Jun;9(6):516-526
pubmed: 28290053
Stem Cell Res Ther. 2010 Dec 14;1(5):39
pubmed: 21156086
Pharmacol Rep. 2020 Feb;72(1):166-178
pubmed: 32016855
Anticancer Res. 2014 Apr;34(4):1931-8
pubmed: 24692728
Int J Biochem Cell Biol. 2019 Jan;106:1-7
pubmed: 30399449
Oncogene. 2012 May 3;31(18):2270-82
pubmed: 21927024
Cancer Manag Res. 2020 Oct 07;12:9735-9739
pubmed: 33116833
Cell Biol Toxicol. 2020 Jun;36(3):273-278
pubmed: 31758290
J Biomed Sci. 2018 Mar 6;25(1):20
pubmed: 29506506
J Investig Dermatol Symp Proc. 2003 Jun;8(1):72-5
pubmed: 12894998
Clin Cancer Res. 2010 May 1;16(9):2580-90
pubmed: 20388854
J Thorac Oncol. 2010 Jan;5(1):29-33
pubmed: 19952801
Expert Opin Drug Deliv. 2017 Aug;14(8):997-1008
pubmed: 27866420
Int J Mol Sci. 2013 Jan 24;14(2):2334-54
pubmed: 23348928
Cancer Res. 2015 Oct 1;75(19):4003-11
pubmed: 26292361
Biomed Pharmacother. 2019 Sep;117:108990
pubmed: 31226638
Am J Transl Res. 2013 Sep 25;5(6):563-81
pubmed: 24093054
Nat Genet. 2008 May;40(5):499-507
pubmed: 18443585
Sci Rep. 2018 Aug 6;8(1):11739
pubmed: 30082842
Biochem Soc Trans. 2020 Feb 28;48(1):301-315
pubmed: 32010943
J Hematol Oncol. 2015 Mar 11;8:23
pubmed: 25879771
Cancer Res. 2019 Dec 15;79(24):6126-6138
pubmed: 31662324
Am J Physiol Cell Physiol. 2015 Jan 15;308(2):C89-100
pubmed: 25411331
Cancer Res. 2003 May 1;63(9):2244-50
pubmed: 12727846
Stem Cell Rev Rep. 2016 Aug;12(4):492-9
pubmed: 27207017
Am J Cancer Res. 2017 Jul 01;7(7):1588-1605
pubmed: 28744407
Methods Mol Biol. 2016;1395:1-18
pubmed: 26910065
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Molecules. 2020 Jan 06;25(1):
pubmed: 31935827
BMJ. 1995 Oct 7;311(7010):899-909
pubmed: 7580546
Integr Med Res. 2017 Jun;6(2):141-148
pubmed: 28664137
Genes Dis. 2016 Mar;3(1):11-40
pubmed: 27077077
J Natl Cancer Inst. 2015 Mar 23;107(6):djv059
pubmed: 25802059
Science. 2005 Feb 18;307(5712):1101-4
pubmed: 15718471
Evid Based Complement Alternat Med. 2015;2015:836564
pubmed: 26339272
Acta Pharmacol Sin. 2017 Jan;38(1):120-132
pubmed: 27773936
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030
Oncotarget. 2010 Nov;1(7):563-577
pubmed: 21317452